JHM Biopharmaceutical

JHM Biopharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on developing next-generation small molecule drugs for metabolic disorders. The company utilizes an advanced platform integrating structure-based drug design (SBDD) and artificial intelligence to accelerate the discovery of highly selective therapeutics. Its lead program, JHM-01, is a potent and selective thyroid hormone receptor beta (THR-beta) agonist designed to treat metabolic dysfunction-associated steatohepatitis (MASH) with improved safety and efficacy profiles. Beyond MASH, JHM is expanding its pipeline to address obesity and type 2 diabetes, leveraging its expertise in metabolic signaling pathways. The company is backed by prominent venture capital firms and operates out of the Suzhou BioBAY industrial park. JHM Biopharmaceutical aims to provide best-in-class oral treatments for chronic metabolic conditions with high unmet medical needs.